The Treatment of Patients Having Spontaneously Occurring Antibodies to Antihaemophilic Factor (Factor VIII)

C.R Rizza; J.O.P Edgcumbe; W.R Pitney; J.A Child

doi:10.1055/s-0038-1649047

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1972; 28(01): 120-128
DOI: 10.1055/s-0038-1649047

Original Article

Schattauer GmbH

The Treatment of Patients Having Spontaneously Occurring Antibodies to Antihaemophilic Factor (Factor VIII)

Authors

C.R Rizza

¹Oxford Haemophilia Centre, Churchill Hospital, Oxford, the Area Department of Pathology, Church Lane, Heavitree, Exeter, the Royal Postgraduate Medical School, London, and St. Bartholomew’s Hospital, London
J.O.P Edgcumbe

¹Oxford Haemophilia Centre, Churchill Hospital, Oxford, the Area Department of Pathology, Church Lane, Heavitree, Exeter, the Royal Postgraduate Medical School, London, and St. Bartholomew’s Hospital, London
W.R Pitney^*

¹Oxford Haemophilia Centre, Churchill Hospital, Oxford, the Area Department of Pathology, Church Lane, Heavitree, Exeter, the Royal Postgraduate Medical School, London, and St. Bartholomew’s Hospital, London
J.A Child

¹Oxford Haemophilia Centre, Churchill Hospital, Oxford, the Area Department of Pathology, Church Lane, Heavitree, Exeter, the Royal Postgraduate Medical School, London, and St. Bartholomew’s Hospital, London

Abstract

Summary

The appearance of antibodies to factor VIII in the blood of previously normal people is a very rare occurrence but when it does happen the haemorrhagic condition which results can be very serious and difficult to treat.

From experience of three cases described here it is recommended that treatment be witheld unless there is serious haemorrhage in which case steroids, large doses of cryoprecipitate or other human AHG should be given. In the case of life endangering haemorrhages it is justified to use the much more potent animal AHG preparations along with an immuno-suppressive drug.

Full Text

References

References
1 Allison A. C. 1970; Tumor development following immuno-suppression. Proceedings of the Royal Society of Medicine 63: 1077.
2 Bidwell E, and Denson K. W. E. 1966; Antibody nature of the inhibitor to antihemophilic globulin. Nature 210: 746.
3 Biggs R, and Bidwell E. 1959; A method for the study of antihaemophilic globulin inhibitors with reference to six cases. British Journal of Haematology 5: 379.
4 Biggs R, Denson K. W. E, and Nossel H. L. 1964; A patient with an unusual circulating anticoagulant. Thrombosis et Diathesis Haemorrhagica 12: 1.
5 Biggs R, and Macfarlane R. G. 1962. Human Blood Coagulation and Its Disorders. 3rd edn.. Blackwell Scientific Publications; Oxford:
6 Brinkhous K. M, Shanbrom E, Roberts H. R, Webster W. P, Fekete L, and Wagner R. H. 1968; A new high-potency glycine precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. Journal of the American Medical Association 205: 613.
7 Cooke J. V, Anderson J. B, and Gamble W. S. 1962; Circulating factor VIII anti-coagulant in bullous Dermatitis. Archives of Internal Medicine 110: 511.
8 Doak P. B, Montgomerie J. Z, North J. D. K, and Smith F. 1968; Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisolone therapy. British Medical Journal IV: 746.
9 Edgcumbe J. O. P. 1968 Study of acquired inhibitor to factor VIII. Abstract of the Simultaneous Sessions XIIth Congress, International Society of Haematology T. T. – 4. p. 182.
10 Ellis H, Handley D. A, and Taylor K. B. 1959; Surgery in a patient with an acquired circulating anticoagulant. Lancet 1: 1167.
11 Frick P. G. 1955; Acquired circulating anticoagulants in systemic “Collagen Disease”. Blood 10: 691.
12 Green D. 1968; Spontaneous inhibitors of factor VIII. British Journal of Haematology 15: 57.
13 Green D. 1971; Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood 37: 381.
14 Horowitz H. I, and Fujimoto M. M. 1962; Acquired hemophilia due to a circulating anticoagulant. American Journal of Medicine 33: 501.
15 Margolius Jr. A., Jackson D. P, and Ratnoff O. D. 1961; Circulating anticoagulants: A study of 40 cases and a review of the literature. Medicine 40: 145.
16 Nilsson I. M, Skanse B, and Gydell K. 1958; Circulating anticoagulant after pregnancy and its response to ACTH. Acta Haematologica 19: 40.
17 Nussey A. M, and Dawson D. W. 1957; Haemophilia-like disease due to an auto-antibody. British Medical Journal 11: 1077.
18 Robboy S. J, Lewis E. L, Schur P. H, and Colman R. W. 1970; Circulating anticoagulants to factor VIII. American Journal of Medicine 49: 742.
19 Shapiro S. S. 1967; The immunologic character of acquired inhibitors of antihaemophilic globulin (factor VIII) and the kinetics of their interaction with factor VIII. Journal of Clinical Investigations 46: 147.
20 Sherman L. A, Goldstein M. A, and Sise H. S. 1969; Circulating anticoagulant (anti-factor VIII) treated with immunosuppressive drugs. Thrombosis et Diathesis Haemorrhagica 21: 249.
21 Whitfield A. G. W, Meynell M. J, Fessey B. M, and Hudson W. A. 1962; A circulating anticoagulant occurring after temporal arteritis and controlled by corticosteroid therapy. Journal of Clinical Pathology 15: 357.
22 Winckelmann G, Bottcher D, and Groh R. 1968; A circulating anticoagulant directed against anti-haemophilic globulin (factor VIII) combined with thrombocytopenia. Thrombosis et Diathesis Haemorrhagica 20: 144.
23 Woodruff M. F. A. 1969; Immuno-suppression and its complications. Proceedings of the Royal Society of Medicine 62: 411.